ESG risk score 28.56
Environmental score 3.52
Social score 19.19
Governance score 5.84
ESG risk category Medium
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Royalty Pharma PLC
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol RPRX:xnas
Currency USD
NASDAQ
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) 22.46%
1 year 52.11%
3 years 30.07%
Data provided by 
Key stats
Price/earnings (LTM) 26.58
Dividend yield (LTM) 1.86%
EPS (LTM) 1.78
Volatility (30 days) 24.07%
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Royalty Pharma PLC
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Sector Healthcare
Industry -
Market cap 20bn
Data provided by /
/ Others were interested in
See all stocksFrequently asked questions
To buy Royalty Pharma PLC stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Royalty Pharma PLC by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Royalty Pharma PLC is RPRX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Royalty Pharma PLC has its primary listing on NASDAQ. You can trade Royalty Pharma PLC with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Royalty Pharma PLC is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Royalty Pharma PLC as part of a broader investment portfolio.